The first patient has been recruited, in Finland, for Alzinova AB’s Phase 1b clinical trial testing its ALZ-101 vaccine for Alzheimer’s disease, the company announced. Alzinova AB, a Swedish biopharma company, is working to develop treatments for Alzheimer’s that specifically target amyloid-beta oligomers — chains of several single…
A biological framework called the “microcompetition model” may explain why people infected with herpes simplex 1 (HSV1) are at increased risk of developing Alzheimer’s disease. “These dynamics explain the observed connection reported in many studies between the virus and Alzheimer’s disease, and provide a framework for further investigations,” researchers…
It took seven years from the time she started showing symptoms for Sophia Rodriguez’s mother to receive a confirmed diagnosis of Alzheimer’s disease. After her death 14 years later, Rodriguez can’t help but wonder how things might have been different had her mother received an earlier diagnosis. Early diagnosis…
Detailed molecular signatures in three mouse models of Alzheimer’s disease at different disease stages allowed for identification of four approved medicines that may be potential Alzheimer’s treatments, a study revealed. The four medications that demonstrated efficiency are now used to treat hypertension (high blood pressure) and inflammation in humans.
In a subset of patients with mild to moderate Alzheimer’s and evidence of severe gum disease due to P. gingivalis infection, treatment with atuzaginstat (COR388) appeared to slow their cognitive decline, according to results from the Phase 2/3 GAIN clinical trial. Across all treated study patients, however, atuzaginstat’s use over about one year failed…
Vivoryon Therapeutics is looking to enroll patients at different stages of Alzheimer’s disease for two ongoing, Phase 2 trials evaluating the safety and efficacy of its investigational oral treatment varoglutamstat. The therapy candidate has shown evidence, in earlier trials, of improving cognition, memory, and attention in Alzheimer’s patients, with…
Every November since President Ronald Reagan’s proclamation in 1983, Americans have been partaking in National Alzheimer’s Disease Awareness Month. These next 30 days will be an opportunity for people to honor the progress made toward understanding and treating the disease while raising money for research and care. It also…
Athira Pharma has completed enrollment in its ACT-AD Phase 2 trial evaluating the safety and efficacy of ATH-1017 in adults with mild-to-moderate Alzheimer’s disease. “The completion of enrollment in our ACT-AD trial is an important step forward in advancing ATH-1017 as a potential new treatment option for patients…
Altoida is starting a five-year study to feed its app-based Precision Neurology device with data from thousands of patients across all stages of Alzheimer’s, to help validate the device’s ability to diagnose the disease at the earliest phases. The device will use artificial intelligence (AI) to collect…
Use of a portable neurostimulator by Actipulse Neuroscience that delivers fast gamma waves to particular brain regions as a way to stop or slow Alzheimer’s disease was found to be safe in a pilot clinical trial. Another trial focused on testing the device’s effectiveness is expected to open early…
Get regular updates to your inbox.